Form 4: Crinetics COO Jeff Knight Boosts Stake with Equity Grants

Crinetics Pharmaceuticals' Chief Operating Officer, Jeff Knight, acquired 34,000 restricted stock units and 55,000 stock options.

Summary

• Jeff E. Knight, Chief Operating Officer of Crinetics Pharmaceuticals, Inc. (CRNX), acquired 34,000 shares of common stock in the form of restricted stock units (RSUs) on February 23, 2026.
• These RSUs were granted at a price of $0 and will vest 25% annually, beginning on March 1, 2027.
• Knight also acquired 55,000 stock options on February 23, 2026, with an exercise price of $43.79 per share.
• The stock options will vest in 48 successive equal monthly installments, commencing from the vesting start date of February 23, 2026, and expire on February 23, 2036.
• Following these transactions, Knight beneficially owns 121,929 shares of common stock, which includes 438 shares acquired under the Issuer's Employee Stock Purchase Plan.
• Knight also beneficially owns 55,000 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. The acquisition of a significant equity stake by a key executive through compensation grants signals management's continued commitment and alignment with shareholder interests, which is generally well-received by investors.

Positives

• The acquisition of restricted stock units and stock options by a key executive like the Chief Operating Officer aligns management's interests with those of shareholders, indicating confidence in the company's long-term prospects.
• The significant grant of 34,000 RSUs and 55,000 stock options represents a substantial equity stake, incentivizing the COO to drive company performance.

Future Outlook

The vesting schedules for both the restricted stock units (25% annually starting March 1, 2027) and stock options (48 equal monthly installments from February 23, 2026) indicate a long-term commitment from the Chief Operating Officer to the company's future performance and growth.

Industry Context

StockSavvy.ai notes that insider equity acquisitions, particularly by high-ranking executives like a Chief Operating Officer, are often interpreted by the market as a positive signal. Such grants align executive incentives with shareholder value creation, a common practice in the biotechnology and pharmaceutical sectors to retain talent and motivate long-term strategic execution.

Stakeholder Impact

• Shareholders may view this as a positive indicator of management confidence and alignment, potentially leading to increased investor sentiment.
• Employees may see this as a sign of stability and long-term vision from the company's leadership.

Next Steps

• Vesting of 25% of restricted stock units annually, commencing March 1, 2027.
• Monthly vesting of stock options over 48 months, commencing February 23, 2026.

Key Dates

Recommendation

While a Form 4 filing detailing executive equity grants is generally a positive signal, indicating management's vested interest in the company's long-term success, it typically does not provide enough information on its own to warrant a 'buy' or 'sell' recommendation. This transaction reinforces a 'hold' position, suggesting that existing investors may maintain their positions given the alignment of executive incentives, but further fundamental analysis is required for a stronger directional call.

Keywords

Crinetics Pharmaceuticals, CRNX, Jeff Knight, Chief Operating Officer, Insider Transaction, Form 4, Restricted Stock Units, Stock Options, Equity Grant, Executive Compensation